Cargando…

MSC Senescence-Related Genes Are Associated with Myeloma Prognosis and Lipid Metabolism-Mediated Resistance to Proteasome Inhibitors

BACKGROUND: Complex carcinogenic mechanisms and the existence of tumour heterogeneity in multiple myeloma (MM) prevent the most commonly used staging system from effectively interpreting the prognosis of patients. Since the microenvironment plays an important role in driving tumour development and M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Yang-Jia, Zheng, Yan-Hua, Li, Qing, Zheng, Jin, Ma, Li-Tian, Zhao, Can-Jun, Li, Tian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711959/ https://www.ncbi.nlm.nih.gov/pubmed/36467498 http://dx.doi.org/10.1155/2022/4705654

Ejemplares similares

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance
por: Weir, Philip, et al.
Publicado: (2023)

Quantitative Phosphoproteomics of Proteasome Inhibition in Multiple Myeloma Cells
por: Ge, Feng, et al.
Publicado: (2010)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Schwestermann, Jonas, et al.
Publicado: (2022)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
por: Soriano, G P, et al.
Publicado: (2016)

Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome
por: Lai, Ruenn Chai, et al.
Publicado: (2012)

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
por: Zhang, Hua, et al.
Publicado: (2022)

Avoiding lentiviral transduction culture induced MSC senescence
por: Pan, Yung-Wei, et al.
Publicado: (2009)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
por: Mitra, A K, et al.
Publicado: (2017)

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Bennett, Melissa K., et al.
Publicado: (2021)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Farrell, Mariah L., et al.
Publicado: (2018)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
por: Park, Jonghoon, et al.
Publicado: (2016)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
por: Paradzik, Tina, et al.
Publicado: (2021)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma
por: Zhou, Hui, et al.
Publicado: (2020)

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
por: Haney, Staci L., et al.
Publicado: (2022)

Tumorigenic Aspects of MSC Senescence—Implication in Cancer Development and Therapy
por: Mojsilović, Slavko, et al.
Publicado: (2021)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
por: Yu, Zhen, et al.
Publicado: (2022)

Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis
por: Bao, Li, et al.
Publicado: (2023)

P953: PHASE I STUDY OF TQB3602 CAPSULE, AN ORAL PROTEASOME INHIBITOR, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Tang, W., et al.
Publicado: (2022)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors
por: Mendonca, Nikolai P., et al.
Publicado: (2016)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells
por: Shalem-Cohavi, Naama, et al.
Publicado: (2019)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
por: Chen, John H., et al.
Publicado: (2017)

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors
por: Nakaue, Emiko, et al.
Publicado: (2023)

A nomogram for predicting prognosis of multiple myeloma patients based on a ubiquitin-proteasome gene signature
por: Ji, Dexiang, et al.
Publicado: (2022)

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2022)

Editorial: The Role of Metabolism in MSC-Mediated Immunomodulation
por: Pers, Yves-Marie, et al.
Publicado: (2021)

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
por: Su, Pan, et al.
Publicado: (2022)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Lipid and glucose metabolism in senescence
por: Liu, Bin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mpa6qeo4m4ko7mu7h17jscvpr1